SCHEMBL8334368

SCHEMBL8334368

Clc1cc(Cl)c2nc(Br)sc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.63
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 3/20 0.51
HPGD P15428 2/20 0.51
HSD17B10 Q99714 2/20 0.51
ALOX15 P16050 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 3/20 0.49
LMNA P02545 4/20 0.37
HTT P42858 2/20 0.36
AKR1B1 P15121 1/20 0.34
MEN1 O00255 2/20 0.33
GAA P10253 2/20 0.33
KMT2A Q03164 2/20 0.33
PKM P14618 1/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10707241 0.81 ALDH1A1 (0.66) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL8311475 0.80 ALDH1A1 (0.42) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL30626878 0.80 ALDH1A1 (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL24603498 0.80 ALDH1A1 (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL8334374 0.78 ALDH1A1 (0.61) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL11109860 0.78 ALDH1A1 (0.61) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL6718517 0.78 ALDH1A1 (1.00) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL2138941 0.77 ALDH1A1 (0.61) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL14880926 0.76 ALDH1A1 (0.46) ALDH1A1RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL19783358 0.76 F2RL3 (0.44) ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116041341-B Quinazoline PAR4 antagonist and medical application thereof 中国药科大学 2025-02-28 CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
US-5888940-A DESICCATING PLANTS BASF AKTIENGESELLSCHAFT (DE) 1999-03-30 US disclosed
EP-0862569-A1 SUBSTITUTED BENZOTHIAZOLS WITH HERBICIDAL ACTION BASF AKTIENGESELLSCHAFT (DE) 1998-09-09 EP disclosed
WO-1997008171-A1 SUBSTITUTED BENZOTHIAZOLS WITH HERBICIDAL ACTION BASF AKTIENGESELLSCHAFT (DE) 1997-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 ALDH1A1 1618/4885RAB9A 667/4885SMN1; SMN2 3677/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 ALDH1A1 1598/4885RAB9A 748/4885SMN1; SMN2 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.